

Anti-ALPPL2-MMAE ADC(Dar4)[SGN-ALPV]


Product Information

Product Name	Anti-ALPPL2-MMAE ADC(Dar4)[SGN-ALPV]
Storage temp.	Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
Catalog# / Size	GM-81151AB-100 / 100 µg GM-81151AB-1mg / 1 mg


Antibody Information

Expression System	CHO
Purity	> 95% as determined by SDS-PAGE
Aggregation	< 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR)	4.0
Endotoxin	<1EU/mg
Sterility	0.22 µm Filtered
Target	ALPPL2
Clone	SGN-ALPV
Alternative Names	ALPPL, ALPPL2, GCAP
Source/Isotype	Monoclonal Human IgG1(KDEL), κ
Application	Positive control of Cytotoxicity Assay
Description	SGN-ALPV is a novel investigational vedotin antibody–drug conjugate composed of a humanized anti-ALPP/ALPPL2 monoclonal antibody, a protease-cleavable linker, and the microtubule disrupting agent monomethyl auristatin E (MMAE). The proposed mechanism of action of SGN-ALPV is binding to ALPP/ALPPL2 on the cell surface, where it is internalized and trafficked to the lysosome. Lysosomal proteases cleave the linker to release MMAE into the cytoplasm, where it binds and disrupts the microtubule network, causing cell cycle arrest and apoptosis.
Formulation	20 mM Histidine, pH 6.0

SDS-PAGE




SEC-HPLC



The purity of this product is greater than 95% verified by SEC-HPLC.

HIC-HPLC



The drug-to-antibody ratio (DAR) of this product is 3.80.

Data Examples

- Cytotoxicity Assay**
- Plating H_ALPPL2 HEK-293 Cell Line (Genomeditech/GM-C26402), 7.5×10^4 cells/mL suspension, and add 100 μ L/well, on the first day.
 - Remove the supernatant of the above-mentioned plated cells.
 - For Anti-ALPPL2-MMAE ADC(Dar4)[SGN-ALPV]: Add 100 μ L drugs (50 μ g/mL) in gradient dilution each well, and incubate at 37 °C for 72 h.
 - Measured the luciferase activities by using GMTiter™ Luminescent Cell Viability Assay (Genomeditech Cat. # GM-040504C) according to recommended protocol.




Fig. assay